What the PCAC Just Did
The July 2026 vote, in plain English
The FDA Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which bulk substances compounding pharmacies are allowed to use — the 503A bulks list. A substance on that list can be compounded for patients; one left off it generally cannot.
On July 23–24, 2026, the committee reviewed seven peptides for the 503A list and recommended six of them: BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon. It declined only DSIP (emideltide). This was a move toward restoring a legal compounding pathway, not restricting one.
Two caveats matter. First, the vote is advisory — the FDA makes the final call through notice-and-comment rulemaking, which takes months, so nothing has changed in law yet. Second, the panel voted over the objections of some of its own FDA scientists, and reporting noted panel members with industry ties. The recommendation is real and positive, but not the last word.
PCAC-Reviewed Compounds — July 2026 Result
| Compound | Status | PCAC Jul 2026 | What it means | |
|---|---|---|---|---|
BPC-157 Body Protection Compound-157 | Rec. for 503A | Recommended 8–6–1 | Positive. Panel backed a legal compounding pathway. FDA rulemaking still pending. | View → |
TB-500 Thymosin Beta-4 fragment | Rec. for 503A | Recommended 8–6–1 | Positive. Most-used recovery peptide; backed for compounding. | |
KPV Lysine-Proline-Valine, α-MSH fragment | Rec. for 503A | Recommended 8–6–1 | Positive. Anti-inflammatory peptide; backed for compounding. | |
MOTS-c Mitochondrial peptide | Rec. for 503A | Recommended 7–5–2 | Positive. Backed despite a closer vote. | |
Semax Nootropic peptide, ACTH fragment | Rec. for 503A | Recommended (Day 2) | Positive. Backed for compounding. | |
Epitalon Epithalon, telomere peptide | Rec. for 503A | Recommended (Day 2) | Positive. Backed for compounding. | |
DSIP Emideltide / delta sleep-inducing peptide | Declined | Voted down 6–7 | Not recommended. The only compound the panel rejected. |
Broader Watchlist & FDA-Approved
| Compound | Status | Notes | What it means |
|---|---|---|---|
CJC-1295 GHRH analog, no DAC | Not yet reviewed | Named in 2026 HHS list | Expected in a future PCAC round; no vote yet. |
Ipamorelin Selective GH secretagogue | Not yet reviewed | Named in 2026 HHS list | Expected in a future PCAC round; no vote yet. |
GHK-Cu Copper peptide | Not yet reviewed | Named in 2026 HHS list | Expected in a future PCAC round; no vote yet. |
AOD-9604 Anti-obesity peptide fragment | Not yet reviewed | Named in 2026 HHS list | Expected in a future PCAC round; no vote yet. |
Thymosin Alpha-1 Tα1, immune modulator | Not yet reviewed | Approved intl. (Zadaxin) | Expected in a future round; no vote yet. |
Tirzepatide Mounjaro / Zepbound | FDA Approved | Off shortage list | Approved drug. Mass compounding under the shortage exemption has wound down. |
Tesamorelin GHRH analog (Egrifta) | FDA Approved | Approved drug | Different pathway from the compounding question. |
Retatrutide LY3437943 | Phase 3 Trial | Not yet approved | Pre-approval. Not compoundable. |
Sermorelin GHRH 1–29 fragment | RUO / compounded | Not in July review | Unchanged by the July vote. |
NAD+ Nicotinamide adenine dinucleotide | RUO Only | Not in July review | Unchanged by the July vote. |
Frequently Asked Questions
Does the July 2026 vote make these peptides legal to compound now?+
Not yet. The PCAC recommendation is advisory. The FDA still has to act on it through notice-and-comment rulemaking before anything changes on the 503A bulks list, which typically takes months. The vote is a strong signal, not a final rule.
Which peptides were recommended, and which was not?+
Recommended for the 503A list: BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon. Declined: DSIP (emideltide), the only one the panel voted down.
What about CJC-1295, Ipamorelin, and GHK-Cu?+
They were not part of the July 23–24 meeting. They were named among the peptides HHS signaled for reconsideration in early 2026, but the committee has not formally reviewed or voted on them. Treat their status as pending a future round.
Does this affect RUO (research-use-only) suppliers?+
Not directly. RUO suppliers are not compounding pharmacies and operate under different statutes. A more favorable compounding status can, however, expand legitimate clinical demand for these compounds.
Where can I find official FDA documentation?+
FDA advisory committee materials and the 503A bulk substance evaluations are published on FDA.gov. This page is a plain-English reference summary and is not affiliated with the FDA.